Merck Pipeline

4Q2025 Reflecting Pipeline to Nov 3, 2025

Lead-in language

The chart below reflects the company's research pipeline as of **Nov 3, 2025**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer, immunology and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.

1. Being developed in a collaboration.
2. Being developed as monotherapy and/or in combination with KEYTRUDA®.

▶ Moved forward since last pipeline update.

Merck pipeline as of Nov 3, 2025

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Biliary Bladder Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Melanoma NSCLC Ovarian Pancreas Prostate patritumab deruxtecan **MK-1022**[1,2]	Alzheimer's Disease **MK-1167**	Alzheimer's Disease **MK-2214**	Cancer Biliary Bladder Breast Cervical CRC Endometrial HCC HNSCC Melanoma NSCLC Ovarian Pancreas ifinatamab deruxtecan **MK-2400**[1]	▶ Cancer Biliary Bladder CRC Esophageal Neoplasm Malignant Pancreatic sacituzumab tirumotecan **MK-2870**[1, 2]
▶ Cancer Bladder **MK-3120**	Cancer Prostate **KEYTRUDA®** **MK-3475**	Cancer Heme (US) **KEYTRUDA QLEX™** **MK-3475A**	PH-COPD **MK-5475**	▶ Cancer Breast Endometrial Ovarian opevesostat **MK-5684**

1. Being developed in a collaboration.
2. Being developed in combination with KEYTRUDA®.

Moved forward since last pipeline update.

Merck pipeline as of Nov 3, 2025

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
COPD ensifentrine (+) glycopyrrolate **MK-5884A**	Cancer Biliary Bladder Cervical CRC Endometrial Gastric NSCLC Ovarian Pancreas RCC SCLC raludotatug deruxtecan **MK-5909**[1]	MASH efinopegdutide **MK-6024**	Cancer SCLC gocatamig **MK-6070**	Cancer Breast **WELIREG™** **MK-6482**
Immunology Axial Spondyloarthritis Hidradenitis Suppurativa Rheumatoid Arthritis Systemic Sclerosis tulisokibart **MK-7240**	Atherosclerosis **MK-7262**	Pulmonary Hypertension due to Left Heart Disease **WINREVAIR™** **MK-7962**	HIV-1 Infection islatravir+ulonivirine **MK-8591B**	Eye Disorders **MK-8748**
Cancer Bladder RCC intismeran autogene **V940**[1, 2]				

Merck pipeline as of Nov 3, 2025

1. Being developed in a collaboration.
2. Being developed in combination with KEYTRUDA®.
3. Being developed as monotherapy and/or in combination with KEYTRUDA®.
4. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials.
5. Available in the U.S. under Emergency Use Authorization.
6. Program is in a Phase 2/3 study.

▶ Moved forward since last pipeline update.

Phase 3	Phase 3	Phase 3	Phase 3	Phase 3
Hypercholesterolemia enlicitide decanoate **MK-0616**	Cancer Breast patritumab deruxtecan **MK-1022**[1]	Cancer Heme nemtabrutinib **MK-1026**	Cancer CRC NSCLC **MK-1084**[2]	Cancer RCC quavonlimab + pembrolizumab **MK-1308A**
Cancer Heme zilovertamab vedotin **MK-2140**	Cancer Esophageal Prostate SCLC ifinatamab deruxtecan **MK-2400**[1]	Cancer Breast Cervical Endometrial Gastric NSCLC Ovarian sacituzumab tirumotecan **MK-2870**[1,3]	Diabetic Macular Edema **MK-3000**[6]	Cancer Hepatocellular (EU) SCLC **KEYTRUDA®** **MK-3475**
Cancer Myeloproliferative Disorders bomedemstat **MK-3543**	Anti-Viral COVID-19 **LAGEVRIO®** **MK-4482**[1, 5] **(US)**	Cancer Prostate opevesostat **MK-5684**	Immunology Crohn's Disease Ulcerative Colitis tulisokibart **MK-7240**	Cancer NSCLC SCLC **LYNPARZA®** **MK-7339**[1, 2]
HIV-1 PrEP **MK-8527**	HIV-1 Infection doravirine + islatravir **MK-8591A** **(EU)**	HIV-1 Infection islatravir+lenacapavir **MK-8591D**[1,4]	Dengue Fever Virus Vaccine **V181**	Cancer Melanoma NSCLC intismeran autogene **V940**[1, 2]

1. MK-3475A to be marketed under the trade name KEYTRUDA SC in the EU.

▶ Moved forward since last pipeline update.

Merck pipeline as of Nov 3, 2025

New Molecular Entities Under Review	**New Molecular Entities** Under Review	**Certain Supplemental Filings** Under Review	**Certain Supplemental Filings** Under Review
Respiratory Syncytial Virus clesrovimab **MK-1654** **ENFLONSIA™** **(EU, JPN)**	Previously Approved Tumors **MK-3475A**[1] **KEYTRUDA QLEX™** **(EU)**	▶ Muscle-Invasive Bladder Cancer who are ineligible for cisplatin-based chemotherapy (KN905) **KEYTRUDA®** **MK-3475** **(US)**	▶ Muscle-Invasive Bladder Cancer who are ineligible for cisplatin-based chemotherapy (KN905) **KEYTRUDA QLEX™** **MK-3475** **(US)**
HIV-1 Infection doravirine + islatravir **MK-8591A** **(US, JPN)**		▶ Platinum-Resistant Recurrent Ovarian Cancer (KNB96) **KEYTRUDA®** **MK-3475** **(US, EU, JPN)**	Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KN689) **KEYTRUDA®** **MK-3475** **(JPN)**

1. Approvals obtained within the last 3 months.

Moved forward since last pipeline update.

Merck pipeline as of Nov 3, 2025

New Molecular Entities Approvals[1]	**New Molecular Entities** Approvals[1]	**Certain Supplemental** Approvals[1]	**Certain Supplemental** Approvals[1]
Previously Approved Solid Tumors **KEYTRUDA QLEX™** **MK-3475A** **(US)**	Pneumococcal Vaccine Elderly Adults (65 yrs and older) (STRIDE-9) **CAPVAXIVE™** **V116** **(JPN)**	Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KN689) **KEYTRUDA®** **MK-3475** **(EU)**	Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KN689) **KEYTRUDA QLEX™** **MK-3475A** **(US)**
		Adults with Pulmonary Arterial Hypertension (PAH, Group 1 Pulmonary Hypertension) (ZENITH) **WINREVAIR®** **MK-7962** **(US)**	HPV Vaccine Male Anogenital Indication **GARDASIL9®** **V503** **(JPN)**
		Pneumococcal Vaccine Adults (18 yrs and older) (STRIDE-8) **CAPVAXIVE™** **V116** **(JPN)**	

Forward-looking statement

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

No duty to update

The information contained in the presentation set forth below was current as of Nov 3, 2025. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after Nov 3, 2025.

The chart reflects the Merck research pipeline as of Nov 3, 2025.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.